Two weeks after agreeing to become part of CRO giant Quintiles ($Q), Novella Clinical is promoting from within to prepare for future growth. Former business optimization and vendor management chief Deborah Turunjian will now serve as vice president of oncology development; Jamie Gault, former quality assurance head, will now helm the company's regulatory affairs division; and Kathleen Zajd, who joined Novella after its 2010 buyout of Prologue Research, will serve as vice president of global quality and compliance. Quintiles expects to close its buyout this quarter. More